New research reveals that Crisaborole can help in reducing atopic dermatitis

Published On : 2017-07-10

Extensive research was carried out to find alternatives for atopic dermatitis treatment. Atopic dermatitis is also referred to as atopic eczema which is a chronic inflammatory disease condition that develops on skin. Atopic dermatitis is most commonly found in children and the costs associated for the treatment of this skin condition is difficult to manage. However, with developments in technology, new platforms emerged and new ways of treating chronic diseases evolved. The rate of people suffering from atopic dermatitis reduced gradually since past few years. Researchers made a point to find the efficacy and safety of the crisaborole ointment to treat atopic dermatitis. It was discovered that atopic dermatitis symptoms can be reduced and the recovery process can be enhanced in both adults as well as children with the application of crisaborole ointment for one month.

There are standard treatments to treat atopic dermatitis which reduce the inflammation and prevent flare ups, they are also associated with certain limitations, for example, thinning of skin with the use of TCS (Topical Corticosteroid) and there also is an increased danger of developing lymphoma with the application of TCI (Topical Calcineurin Inhibitor). These limitations prove hazardous to people suffering from AD (Atopic Dermatitis); while curing one disease, they tend to develop another and hence new ways and therapies for treating atopic dermatitis which are effective and safe were researched upon. The patients or participants were those people who had mild to moderate atopic dermatitis. These people were given crisaborole or placebo ointment and their caregivers were instructed to apply these ointments, except the scalp area, twice a day for almost 30 days. Effectiveness of the treatment was assessed with the help of ISGA (Investigator’s Static Global Assessment) score that rates the severity of atopic dermatitis from zero to four. Based on the vitals of the patient, safety measures were assessed with respect to adverse events. Redness, oozing, skin picking, leathery skin and hardening and bumps were reduced to a good extent. To infer, crisaborole can be used to treat atopic dermatitis which reduces its symptoms and accelerates recovery in children as well as adults. There are few side effects, but they are short lived and mild and do not pose danger conditions to the patient. Crisaborole has a good potential to serve as an effective and a safer option and can be applied to children and also individuals who suffer from severe atopic dermatitis.